Drugs Used to Treat Parkinson’s Disease By Jasmine and Morgan 11/13/03.

Slides:



Advertisements
Similar presentations
Drugs That Act On The Central Nervous System SAMUEL AGUAZIM( MD)
Advertisements

Diagnosis and Management of Parkinson’s Disease
ILOs At the end of this lecture you will be able to:- Recognize the symptoms and pathophysiology of parkinsonism. Understand the pharmacology of drugs.
ILOs At the end of this lecture you will be able to:- Revew the symptoms and pathophysiology of parkinsonism. Detail on the pharmacology of drugs used.
Parkinson’s Disease (PD)
An Overview of Conventional and Experimental Treatments
Movement part 2. Cerebellum and Brainstem KW p. 363.
Brain Control of Movement. Motor Control Hierarchy  High level – plans and executes strategy Association areas of cortex Basal ganglia gives the “go”
PHL 437/Pharmacogenomics Fourth Lecture (Parkinson’s disease) By Abdelkader Ashour, Ph.D. Phone:
Initial Diagnosis and Management of Parkinson’s Disease
Module 7.3 Movement Disorders. Parkinson’s Disease A neurological disorder characterized by muscle tremors, rigidity, slow movements and difficulty initiating.
Parkinson’s Disease and Treatment Shalla Hanson Medicinal Chemistry April 2009.
Erica Partridge Parkinson’s Disease. Definition Aetiology PD vs Parkinsonism Symptoms and signs Differentials Investigations Management Prognosis.
Parkinson ’ s disease. Function Anatomy of Parkinson ’ s Disease.
JP Parkinson’s Disease. Overview Idiopathic PD Clinically and pathologically distinct from other parkinsonian syndromes Degenerative disorder of the CNS.
Parkinson’s Disease By Devin Cornford
Mosby items and derived items © 2011, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. CHAPTER 16 Antiparkinsonian Drugs.
Parkinson ’ s A Review and Practical Guide to a Common and Complex Disease.
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. CHAPTER 14 Antiparkinsonian Drugs.
Chapter 30 Agents Used to Treat Parkinson’s Disease.
Drugs for Parkinon’s disease Parkinson's disease –progressive tremor –Bradykinesia and rigidity –degeneration of the dopaminergic nigrostriatal pathway.
Drugs of Anti-Parkinson’s disease Department of Pharmacology Zhang Yan-mei.
Treatment of Parkinson’s Disease Thomas L. Davis, M.D. Associate Professor of Neurology Vanderbilt School of Medicine.
By Prof. Hanan Hagar Pharmacology unit Medical College.
PhD MD MBBS Faculty of Medicine Al Maarefa Colleges of Science & Technology Faculty of Medicine Al Maarefa Colleges of Science & Technology Lecture – 9:
Adult Medical-Surgical Nursing Neurology Module: Parkinson’s Disease.
Salvador Dali (Painter) Mao Zedong (Chinese Politician) Michael J Fox (Actor) Pope John Paul II Muhammad Ali (Boxer) Janet Reno (Former AG)
Treatment of Parkinson’s Disease Christopher Buchanan CHEM 5398/Buynak April 3, 2007.
Benjamin L. Walter M.D. Medical Director, Deep Brain Stimulation Program Neurological Institute University Hospitals Case Medical Center Management of.
BASAL GANGLIA Basal ganglia are subcorticle nuclei of grey matter located in the interior part of cerebrum near about base 3.
Parkinson’s Disease Dr. Andrew Schmelz, PharmD Post-Doctoral Teaching Fellow Dept of Pharmacy Practice Purdue University March 4, 2009.
Slide 1 Mosby items and derived items © 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. Chapter 15 Drugs Used for Parkinson’s Disease.
Drugs used in parkinsonism
By Prof. Hanan Hagar Pharmacology unit Medical College.
 Parkinson’s Disease (PD) -progressive neurodegenerative disease affecting motor ability -third most common neurologic disorder of older adults.
1 Parkinson’s Disease (PD): Levodopa Drug Treatment Presenter: Pedro Da Silva Date: February 27, 2007.
By Prof. Hanan Hagar Pharmacology unit Medical College.
Parkinson's Disease ILOs
Drugs in parkinsonism ilos
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. CHAPTER 14 Antiparkinsonian Drugs.
Parkinson’s Disease Angela Duncan June Why I Chose This Subject Common neurodegenerative disorder / in Scotland Expected increase.
Drugs Used for Parkinson’s Disease Chapter 15 Mosby items and derived items © 2010, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc.
Pathogenesis and pathology of parkinsonism
ANTI- PARKINSONISM Dr: Samah Gaafar Al-shaygi.  Neurodegenerative diseases.  Dopamenergic neurones in substantia nigra.  Environmental* genetic factors.
 Parkinson’s disease is a neurodegenerative disorder first described by Dr James Parkinson, a London physician, in The underlying cause is loss.
Brain Mechanisms of Movement Lecture 19. Hierarchical Control of Movement n Association cortices & Basal Ganglia l strategy : goals & planning l based.
Neurotransmitters in the Brain. What are the different neurotransmitters in the brain? Currently, over 60 different molecules meet the criteria for being.
ANTI-PARKINSONIAN DRUGS. Parkinsonism It is a common movement disorder that involves dysfunction in the basal ganglia and associated brain structures.
항 파킨슨씨 약물 Anti-Parkinson Drug.
PARKINSON’S DISEASE CHAMINDA UNANTENNE RN,MS,MSN.
Parkinson’s disease by Syed Baseeruddin Alvi (09).
A Primer for Clinicians and Administrators
Drugs Used for Parkinson’s Disease
Parkinson’s Disease.
Parkinsonism.
Module 7.3 Movement Disorders
DRUGS FOR PARKINSONISM
Drugs of Anti-Parkinson’s disease
Lecture 3 Dr.Narmin Hussen
Drugs for Parkinson’s Disease
Treatment of Parkinson’s disease
“The effects of chronic changes to the functioning of the nervous system due to interference to neurotransmitter function, illustrated by the role of Dopamine.
Parkinson’s disease.
ANTIPARKINSONS Drugs By Dr. Mirza Shahed Baig.
Central Nervous System
Parkinsonism and Anesthesia
Drugs for Degenerative Diseases of the Nervous System
Classification of Epilepsy (p. 227)
Neurodegenerative diseases
Deep Brain Stimulation: What, When, Why, How
Presentation transcript:

Drugs Used to Treat Parkinson’s Disease By Jasmine and Morgan 11/13/03

Parkinson’s Disease subtypes Idiopathic Parkinson’s disease Idiopathic Parkinson’s disease – Primary (unknown origin) ParkinsonismParkinsonism – Secondary (known origin) – drugs, stroke, trauma FamilialFamilial – (genetic origin)

Subclinical hypodopaminergic state Subclinical hypodopaminergic state - loss of 80-90% of DA neurons before symptoms present (roughly 20 years) DA neuronal loss not from Basal Ganglia - DA neuronal loss not from Basal Ganglia - loss of dopaminergic input to Striatum Neuronal death observed in Substantia Nigra (Pars Compacta) and the Nigrastriatal bundle A9 DA System DA content decrease in extra pyramidal motor areas of basal ganglia Caudate and putamen

Substantia Nigra, Normal. Pigment Loss Is Seen In Parkinson's Disease

Rodent Brain A9 System

1 % Prevalence in Adult Population- Age 65 and Older As many as 10% aged 60 and older may have undiagnosed early stages of the disease Increased onset due to – Transitory Ischemic Attacks (TIA) – Brain Damage – Drug Abuse 1 ½ times more prevalent in women

Cardinal Symptoms Bradykinesia Bradykinesia - Slowness and poverty of movement “Cogwheel” rigidity Muscle “Cogwheel” rigidity Resting tremor Abates during voluntary movement Shuffling gait Impairment of postural balance

Secondary Symptoms Dementia Visuospatial deficits, impaired attention and executive function Anxiety Sleep disturbances Sexual dysfunction Abnormal theromregulation

Therapy Therapy see table18.2 pg534 Levodopa Levodopa (L-dopa) Rapid oral absorption – 95% converted to DA in plasma DA doesn’t cross BBB from plasma into CNS Precursor L-dopa does cross BBB via active transport system (about 5%) Most effective current treatment

Problems Associated with L-Dopa Decrease high levels of DA in periphery that can cause nausea by inhibiting dopa decarboxylase which converts dopa to DA Carbidopa Carbidopa – Peripheral decarboxylase inhibitor Carbidopa/ levodopa combo reduces the amount necessary for therapeutic level of L-Dopa by 75%

Problems Associated with L-Dopa Even with carbidopa, much of L-Dopa converted by COMT (in GI tract and Liver) to inactive metabolic by- product Recent addition of peripheral COMT inhibitors to standard treatment – Talcapone and Entacapone Increase the half-life and prolong the effects of L- Dopa –A few cases of serious liver toxicity attributed to Talcapone (1998) – Entacapone too new to say (2000)

Limitations to L-dopa Therapy Becomes less effective as time goes on “on-off”/ “wearing off” effect between 1-5 yrs patients on L-dopa therapy gradually become less responsive Results in hypermovement, then hypomovement, then no movement (akinesia) Taking doses more often, or taking large doses results in dyskinesias (uncontrolled movements) and may result in psychiatric complications. On-off effect possibly related to DA neurons inability to synthesize and store DA

DA Receptor Agonists Bind to postsynaptic striatal neurons Possible use for early and late stages Four currently available Bromocriptine (1978) and Pergolide (1989) Derived from lysergic acid, structurally similar to DA –Marginally effective with numerous side effects –Affinity for D2 receptors (Inhibitory)

DA Receptor Agonists Pramipexole and Ropinirole (1997) Affinity for D3 receptors (Inhibitory) Indicated for use in early onset Increased safety and efficacy over older agonists (although risk of sleep attacks) Long half lives may partially explain reduction in on-off effect Side effects: hallucinations, insomnia, nausea, somnolence and dizziness. Long term use of DA agonists results in increased sensitivity of DA receptors (sensitization)

Additional Therapies Selegiline Selectively inhibits MAO-B (preferential affinity for DA neurons) Used in newly diagnosed, younger patients Appears to slow disease progression and delay need for L-Dopa Metabolized to several by-products, including amphetamine and methamphetamine In combo with L-Dopa, may result in increased morbidity after 5 years

Additional Therapies Muscarinic Receptor Antagonists Widely used before L-Dopa Still used as an adjunct to L-Dopa for severe tremors Cognitive dysfunction limits their use Experimental Brain Surgery Lesions (thalamus and GPi) Neural tissue implants (fetal substantia nigra neurons) Transplantation of carotid body glomus cells (secrete DA) to the putamen

Dopaminergic substantia nigra neurons continue to die, until they’re all gone.

Thank You ……now it’s your turn Q&A!!!